A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.
Nafarelin has been studied across 17 research domains including 🧬 Hormones, ♀♂ Sexual Health, 👁️ Vision & Eye, 💪 Strength & Power, 🔬 Oncology. The primary research focus is 🧬 Hormones with 38% of studies addressing this area.
This evidence profile for Nafarelin is generated deterministically from 269 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.